Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Trenton, NJ
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Trenton, NJ
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
New York, NY
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Staten Island, NY
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Durham, NC
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Mooresville, NC
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Mooresville, NC
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Fargo, ND
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Bend, OR
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Medford, OR
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Beaver, PA
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Beaver, PA
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Scranton, PA
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Scranton, PA
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Kingsport, TN
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Kingsport, TN
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
South Burlington, VT
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
South Burlington, VT
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Richmond, VA
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Spokane, WA
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Vancouver, WA
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Waukesha, WI
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Waukesha, WI
Click here to add this to my saved trials
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated:  8/1/2016
mi
from
Camperdown,
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status: Enrolling
Updated: 8/1/2016
mi
from
Camperdown,
Click here to add this to my saved trials
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
Effect of Renal Impairment on Pharmacodynamics and Pharmacokinetics of RO4998452: A Multiple-center, Open-label, Parallel Group Study Following Single Oral Dosing of RO4998452 to Type 2 Diabetes Patients With Varying Degrees of Renal Impairment.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Renton, WA
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
Effect of Renal Impairment on Pharmacodynamics and Pharmacokinetics of RO4998452: A Multiple-center, Open-label, Parallel Group Study Following Single Oral Dosing of RO4998452 to Type 2 Diabetes Patients With Varying Degrees of Renal Impairment.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Renton, WA
Click here to add this to my saved trials
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
Effect of Renal Impairment on Pharmacodynamics and Pharmacokinetics of RO4998452: A Multiple-center, Open-label, Parallel Group Study Following Single Oral Dosing of RO4998452 to Type 2 Diabetes Patients With Varying Degrees of Renal Impairment.
Status: Enrolling
Updated:  8/1/2016
mi
from
Moscow,
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
Effect of Renal Impairment on Pharmacodynamics and Pharmacokinetics of RO4998452: A Multiple-center, Open-label, Parallel Group Study Following Single Oral Dosing of RO4998452 to Type 2 Diabetes Patients With Varying Degrees of Renal Impairment.
Status: Enrolling
Updated: 8/1/2016
mi
from
Moscow,
Click here to add this to my saved trials
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Anaheim, CA
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chula Vista, CA
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Ft. Myers, FL
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Ft. Myers, FL
Click here to add this to my saved trials
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Miramar, FL
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Miramar, FL
Click here to add this to my saved trials
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 in Patients With Type 2 Diabetes Mellitus on Stable Background Therapy
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 in Patients With Type 2 Diabetes Mellitus on Stable Background Therapy
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
A Randomized, Placebo-Controlled, Sequential, Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR701/RO6807952 in Type 2 Diabetic Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chula Vista, CA
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
A Randomized, Placebo-Controlled, Sequential, Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR701/RO6807952 in Type 2 Diabetic Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
A Randomized, Placebo-Controlled, Sequential, Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR701/RO6807952 in Type 2 Diabetic Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
A Randomized, Placebo-Controlled, Sequential, Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR701/RO6807952 in Type 2 Diabetic Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of RO6807952 in Type 2 Diabetic Patients Inadequately Controlled With Metformin Alone
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of RO6807952 in Type 2 Diabetic Patients Inadequately Controlled With Metformin Alone
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Ohio, OH
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Ohio, OH
Click here to add this to my saved trials
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  8/8/2016
Hanmi pharmaceutical
mi
from
CA, CA
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 8/8/2016
Hanmi pharmaceutical
mi
from
CA, CA
Click here to add this to my saved trials
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin
Status: Enrolling
Updated:  8/8/2016
Hanmi pharmaceutical
mi
from
Miami, FL
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin
Status: Enrolling
Updated: 8/8/2016
Hanmi pharmaceutical
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes
Effect of Pulsatile IV Insulin Delivery on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes
Status: Enrolling
Updated:  8/8/2016
Florida Atlantic University Center for Complex Systems and Brain Sciences
mi
from
Boca Raton, FL
Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes
Effect of Pulsatile IV Insulin Delivery on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes
Status: Enrolling
Updated: 8/8/2016
Florida Atlantic University Center for Complex Systems and Brain Sciences
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Hudson Heart Group, PC
mi
from
Guttenberg, NJ
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Hudson Heart Group, PC
mi
from
Guttenberg, NJ
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Elmhurst Hospital
mi
from
Elmhurst, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Elmhurst Hospital
mi
from
Elmhurst, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Winthorp University Hospital
mi
from
Mineola, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Winthorp University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated:  8/10/2016
Stony Brook University Hospital
mi
from
Stony Brook, NY
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes
Status: Enrolling
Updated: 8/10/2016
Stony Brook University Hospital
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated:  8/15/2016
University of Missouri, Department of Internal Medicine
mi
from
Columbia, MO
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated: 8/15/2016
University of Missouri, Department of Internal Medicine
mi
from
Columbia, MO
Click here to add this to my saved trials
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  8/16/2016
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 8/16/2016
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  8/16/2016
National Research Institute
mi
from
Los Angeles, CA
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 8/16/2016
National Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  8/16/2016
NRC Research Institute
mi
from
Orange, CA
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 8/16/2016
NRC Research Institute
mi
from
Orange, CA
Click here to add this to my saved trials
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  8/16/2016
Sierra Clinical Research
mi
from
Roseville, CA
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 8/16/2016
Sierra Clinical Research
mi
from
Roseville, CA
Click here to add this to my saved trials
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  8/16/2016
Encompass Clinical Research
mi
from
Spring Valley, CA
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 8/16/2016
Encompass Clinical Research
mi
from
Spring Valley, CA
Click here to add this to my saved trials
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  8/16/2016
Empire Clinical Research
mi
from
Upland, CA
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 8/16/2016
Empire Clinical Research
mi
from
Upland, CA
Click here to add this to my saved trials
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated:  8/16/2016
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Status: Enrolling
Updated: 8/16/2016
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Click here to add this to my saved trials